Nowtransit INC 10-Q quarterly reports

BioScience Health Innovations Inc. reported a net loss of $185,753 for the three months ended June 30, 2026, with revenues falling to $1,036,364 from $1,757,463 in the prior year period.

BioScience Health Innovations Inc. reported a net loss for the first quarter of 2026, with revenues declining year-over-year, attributed to sales channel adjustments and a rescheduled major order, while advancing its patent-pending product pipeline.

BioScience Health Innovations Inc. reported significant revenue and net income growth for the nine months ended September 30, 2025, driven by strategic initiatives and product development, despite a net loss in the most recent quarter.

BioScience Health Innovations Inc. reported significant revenue and net income growth for Q2 2025, driven by increased sales and marketing efforts, despite ongoing concerns about its ability to continue as a going concern.

BioScience Health Innovations Inc. reports a significant turnaround with net income of $426,798 for Q1 2025, compared to a net loss in the same period last year, driven by increased revenue and strategic initiatives.

Nowtransit Inc. achieved a profitable quarter ending September 30, 2024, driven by increased sales and marketing efforts, despite ongoing concerns about its ability to continue as a going concern.

Nowtransit Inc. reports a profitable second quarter with a net income of $74,222, driven by increased sales and marketing efforts.

Nowtransit Inc. reports its financial results for the quarter ended February 28, 2023, and details the completion of a reverse merger with Best Labs Inc.

Nowtransit Inc. saw a significant increase in revenue in the first quarter of 2024 compared to the same period last year, but continues to operate at a loss.